PROTAC PAPD5 degrader 1

• UNSPSC Description:

  PROTAC PAPD5 degrader 1 (compound 12b) inhibits both hepatitis A (HAV) and hepatitis B virus (HBV) in vitro and in vivo[1], with IC50 and CC50 of 10.59 μM and ＞ 50 μM, respectively in Huh7 cells[1].

• Target Antigen:

  HBV; PROTACs

• Type:

  Reference compound

• Related Pathways:

  Anti-infection;PROTAC

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/protac-papd5-degrader-1.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(C1=CN([C@H](C(C)C)CC2=C3C=C(OC)C(OCCCNC(CCOCCOCCOCCOCCOCCOCCNC4=CC=CC(C(N5C(CC6)C(NC6=O)=O)=O)=C4C5=O)=O)=C2)C3=CC1=O)O

• Molecular Weight:

  978.05

• References & Citations:

  [1]You Li, et al. “PROTAC” modified Dihydroquinolizinones (DHQs) that causes degradation of PAPD-5 and inhibition of hepatitis a virus and hepatitis B virus, in vitro. Bioorg Med Chem Lett. 2024 Feb 29:102:129680.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported